A 56-Day Single-Arm Exploratory Study of NatureU Mind Care BeautyU Caps on Crow's-Feet Wrinkle Count, Skin Hydration, and Related Skin-Aging Parameters in Adult Women

BackgroundSkin aging is multifactorial, and finished multi-ingredient oral beauty supplements require dedicated clinical evaluation because their effects cannot be inferred from individual ingredient data alone. ObjectiveTo explore, in a 56-day single-arm open-label study, whether daily oral intake of NatureU(R) Mind Care BeautyU Caps is associated with within-participant changes in crows-feet wrinkle count (primary endpoint), stratum corneum hydration (secondary endpoint), and additional exploratory skin-aging parameters in adult women. MethodsA single-center, open-label, single-arm exploratory study enrolled 33 healthy women aged 36-56 years, eligible only if baseline cheek hydration was below 60 corneometer units (C.U.); 31 completed the protocol. Participants took one capsule orally once daily for 56 consecutive days. Assessments at D0, D28 and D56 used PRIMOS CR, Corneometer CM 825, Cutometer MPA580, Glossymeter, Colorimeter CL400, Mexameter MX18, VISIA CR, DermaScan and a structured self-assessment. ResultsPRIMOS CR crows-feet wrinkle count fell from 965.3 {+/-} 333.7 at D0 to 514.2 {+/-} 171.0 at D56 (-46.73%; Wilcoxon P = 1.2 x 10{square}{square}), and Corneometer hydration rose from 44.3 {+/-} 7.8 to 70.3 {+/-} 9.9 (+58.57%; P = 1.2 x 10{square}{square}). Both changed in all 31 completers. Average wrinkle depth changed only non-significantly (-4.81%; P = 0.058), decreasing in 19 participants, increasing in 11 and unchanged in one. Individual-participant data obtained after version 1 show that the reduction in wrinkle count was almost exactly proportional across a 5.9-fold range of baseline values (D56/D0 ratio 0.535 {+/-} 0.041; coefficient of variation 7.7%, lower than any other endpoint), was uncorrelated with baseline severity (r = -0.15, P = 0.42), was complete by D28 (D56/D28 ratio 0.990 {+/-} 0.096), and was uncorrelated with the change in wrinkle depth (r = +0.30, P = 0.096) or hydration (r = +0.23, P = 0.21). No adverse reactions were reported. ConclusionDaily intake over 56 days was associated with an increase in stratum corneum hydration that cannot be accounted for by the low-hydration entry criterion alone. A reduction in crows-feet wrinkle count was also recorded, but its uniformity across participants, its independence of baseline severity, its completion at the first follow-up visit, and the absence of the analysis parameters needed to reproduce it mean that the authors do not interpret it as evidence of a biological anti-wrinkle effect. This conclusion supersedes that of version 1. Findings are hypothesis-generating; randomized, placebo-controlled trials are required. Version note -- what changed and whyThis version revises version 1 following peer review of the same study. Readers should not rely on version 1. Six substantive changes have been made. O_LIThe interpretation of the primary endpoint has changed After version 1 was posted, the authors obtained the individual-participant dataset from the contract testing organization. It shows that the reduction in crows-feet wrinkle count occurred in all 31 completers, was almost exactly proportional across a 5.9-fold range of baseline values, was uncorrelated with baseline severity, was complete at day 28 with no further progression, and was uncorrelated with the concurrent change in wrinkle depth or hydration. The acquisition and analysis parameters needed to exclude a measurement explanation -- the PRIMOS segmentation threshold, the region-of-interest definition and whether images were spatially registered across timepoints -- were requested from the contract testing organization and were not provided. The authors therefore no longer interpret the reduction in wrinkle count as evidence of a biological anti-wrinkle effect. Version 1 did interpret it that way; that interpretation is withdrawn. C_LIO_LIThe description of the ethics committee has been corrected Version 1 described the review body as a "dedicated ethics oversight body". It is the internal ethics committee of the contract testing organization that conducted the study under commission from, and for payment by, the sponsor. The corrected Ethics statement below says so explicitly. C_LIO_LIThe trial registration statement has been corrected Version 1 contained an internal inconsistency: the body text stated that the study "was not prospectively registered", while the submission metadata gave a registration identifier and answered the registration declaration affirmatively without the explanation that medRxiv requires for retrospectively registered studies. The corrected statement below gives the registration date and the interval. C_LIO_LIThe conflict-of-interest statement has been made specific Version 1 stated only that authors affiliated with the sponsor "declare those relationships in accordance with the journals disclosure requirements", which disclosed nothing. The corrected statement below names the relationships. C_LIO_LIAn appendix has been removed Version 1 reproduced, in full, an administrative document titled "Ethics Review and Regulatory Classification Report", including a regulatory classification of the product under Hong Kong law. That document is not study content, its regulatory classification is not a finding of this study, and its description of the ethics committee is superseded by item 2 above. It has been removed. It remains available in version 1 for anyone who wishes to consult it. C_LIO_LIThe author byline has been corrected Version 1 listed four authors in the manuscript byline. One of those names, Miexin Yang, was included in the manuscript file in error: that person did not contribute to the work reported here and was never registered as an author in the submission record, which has listed three authors throughout. The byline in this version therefore lists the three authors of record -- Lorry Luo, Luke Law and Naining Zhang -- and now matches the submission metadata. No author has been added, and no author who contributed to the work has been removed. C_LI The affiliation of Naining Zhang has been updated from "CTI AiPu Medical Laboratory (Shanghai) Co., Ltd." to "Centre Testing International Pinbiao (Shanghai) Co., Ltd.". These are two English renderings of the same legal entity; the latter is the name that appears on the ethics approval and is used throughout this version. Figures and tablesVersion 1 contained two figures and no data tables. This version retains both (Figure 1 has been redrawn so that the three columns are no longer joined by causal arrows, because no such link was measured) and adds Figure 3 and Tables 1-5, which present the underlying summary data in full. Two panels of photographic material that accompanied version 1s supplementary documentation -- a commercial wrinkle-grading reference scale and example instrument output images -- have not been carried over, since they are photographs of skin and are not required to follow the analysis. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=117 SRC="FIGDIR/small/26351904v2_fig1.gif" ALT="Figure 1"> View larger version (43K): org.highwire.dtl.DTLVardef@1a1f635org.highwire.dtl.DTLVardef@2b25e6org.highwire.dtl.DTLVardef@c55db3org.highwire.dtl.DTLVardef@18aa6a7_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 1.C_FLOATNO Composition, literature-reported mechanisms, and measured endpoint domains. The three columns list, respectively, what was administered, the mechanisms reported for these ingredients in the published literature, and the endpoint domains measured in this study. The columns are deliberately presented without connecting arrows: no link between an ingredient, a mechanism and an endpoint was measured or tested here, and none is asserted. Column 2 states why the combination was assembled and is not evidence about this product; no biomarker, absorption or tissue-exposure measurement was performed. Colour is used only to distinguish what was measured in this study (teal, columns 1 and 3) from what was not measured (gold, column 2). C_FIG O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=149 SRC="FIGDIR/small/26351904v2_fig3.gif" ALT="Figure 3"> View larger version (40K): org.highwire.dtl.DTLVardef@1c3530corg.highwire.dtl.DTLVardef@815988org.highwire.dtl.DTLVardef@1d0898org.highwire.dtl.DTLVardef@1f72d0_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 3.C_FLOATNO Individual-participant trajectories over 56 days in the 31 completers. (a) Crows-feet wrinkle count, the prespecified primary endpoint. (b) Stratum corneum hydration, the prespecified secondary endpoint; the dashed line marks the 60 C.U. entry criterion. (c) Average wrinkle depth. (d) Day 56 versus baseline wrinkle count, with the line of identity and the fitted regression. Faint lines and points are individual participants; the heavy line shows mean {+/-} standard deviation. Panels (a) and (d) show that the count fell in every participant by a near-constant proportion irrespective of baseline value, and panel (a) that the change was complete by day 28. This pattern is discussed in Section 4.1. No participant identifiers are shown. C_FIG O_TBL View this table: org.highwire.dtl.DTLVardef@aae1dcorg.highwire.dtl.DTLVardef@d24866org.highwire.dtl.DTLVardef@18f3daeorg.highwire.dtl.DTLVardef@11aa6ceorg.highwire.dtl.DTLVardef@bd2621_HPS_FORMAT_FIGEXP M_TBL O_FLOATNOTable 1.C_FLOATNO O_TABLECAPTIONStudy design, endpoint hierarchy, participant disposition and tolerability. C_TABLECAPTION C_TBL O_TBL View this table: org.highwire.dtl.DTLVardef@12504borg.highwire.dtl.DTLVardef@557638org.highwire.dtl.DTLVardef@c47680org.highwire.dtl.DTLVardef@3ffd14org.highwire.dtl.DTLVardef@100607d_HPS_FORMAT_FIGEXP M_TBL O_FLOATNOTable 5.C_FLOATNO O_TABLECAPTIONParticipant-reported recognition rates for questionnaire items 1-19 (n = 31 completers), with P values recomputed by the authors using a two-sided exact binomial test against the prespecified 60% benchmark. Recognition rate is the proportion of participants selecting an agreement-level response. The D28 P values differ from those in the original testing report for the reason given in Section 2.6. Item wording is given in Appendix Table A2. C_TABLECAPTION C_TBL Three numerical corrections have also been made. Wrinkle depth decreased in 19 of 31 participants, increased in 11 and was unchanged in one; version 1 and an earlier draft of this version reported "12" increases, which omitted the unchanged participant. Percentage changes are now computed throughout from unrounded means, which changes the reported day-28 hydration increase from +65.01% to +64.77%; the testing report computed these percentages from means rounded to one decimal place. The correlation statistics now state the quantity on which each was computed. The study data are unchanged. No participant data, measurement or summary statistic has been altered; the recomputed values reported below were derived by the authors from the individual-participant dataset.